Document is current
Any future updates will be listed below
-
Authors
Jacquelot, N.
Roberti, M. P.
Enot, D. P.
Rusakiewicz, S.
Ternès, N.
Jegou, S.
Woods, D. M.
Sodré, A. L.
Hansen, M.
Meirow, Y.
Sade-Feldman, M.
Burra, A.
Kwek, S. S.
Flament, C.
Messaoudene, M.
Duong, C. P. M.
Chen, L.
Kwon, B. S.
Anderson, A. C.
Kuchroo, V. K.
Weide, B.
Aubin, F.
Borg, C.
Dalle, S.
Beatrix, O.
Ayyoub, M.
Balme, B.
Tomasic, G.
Di Giacomo, A. M.
Maio, M.
Schadendorf, D.
Melero, I.
Dréno, B.
Khammari, A.
Dummer, R.
Levesque, M.
Koguchi, Y.
Fong, L.
Lotem, M.
Baniyash, M.
Schmidt, H.
Svane, I. M.
Kroemer, G.
Marabelle, A.
Michiels, S.
Cavalcanti, A.
Smyth, M. J. https://orcid.org/0000-0001-7098-7240
Weber, J. S.
Eggermont, A. M.
Zitvogel, L.
- License Information
-
More Information
Article History
Received: 1 February 2017
Accepted: 10 July 2017
First Online: 19 September 2017
Competing interests
: L.C. receives consulting fees from Medimmune and Pfizer and patent/licensing payments from Bristol-Myers Squibb (BMS); L.C. currently receives sponsored research funding from Boehringer Ingelheim, Pfizer and Nextcure. L.F. received research funding from BMS, Merck, Medimmune, Abbvie and Genentech. S.D. is principal investigator, received research grants and congress invitation by BMS. B.W. reports research grants, speaker honoraria, and travel support from MSD/Merck and BMS. I.M. has served as an advisor for Roche-Genentech, BMS, Boehringer Ingelheim, Novartis, Astra-Zeneca Medimmune and Incyte. AME participated on scientific advisory boards for Actelion, Agenus, Bayer, BMS, GlaxoSmithKline (GSK), HalioDx, Incyte, MSD, Nektar, Novartis, Pfizer, and Sanofi. L.Z. is on the Transgene administrative board and Lytix Pharma scientific advisory board and is the main founder of EverImmune. M.J.S. has research agreements with BMS and Corvus Pharmaceuticals and has received patent payments from BMS. A.M.D.G. has honoraria for certified continuing education, and travel supports from BMS, Astra-Zeneca, Roche and MSD. M. Maio has honoraria for certified continuing education, for consulting and advisory roles, research funding and travel supports from BMS, Roche and MSD. A.C.A. is a member of the SAB for Tizona Therapeutics, Potenza Therapeutics, and Idea Pharmaceuticals, which have interests in cancer immunology. A.K. received congress invitation from BMS. C.B. reports honoraria from Lilly, BMS and MSD, serves as advisory roles from Servier and Roche and receives research grants from Roche. B.D. reports BMS board participation, investigator for BMS clinical trials and congress invitation. Y.K. reports ownership interest in a patent regarding serum biomarkers for ipilimumab treatment (WO2016127052.A1). M.H. is a full time employee of Symphogen A/S Denmark. IMS reports honoraria for teaching, consultancy, and advisatory roles from BMS, Roche, Novartis, Genentech, and MSD, research agreement with BMS, Novartis, and Symphogen and co-founder of IO Biotech. R.D. receives research funding from Novartis, MSD, BMS, Roche, GSK and has a consultant or advisory board relationship with Novartis, MSD, BMS, Roche, GSK, Amgen, Takeda, Pierre Fabre. M.B., Y.M., and M.S.F. were supported by the NORFAR program, the Academic Research Office of the Chief Scientist, Ministry of Economy, Israel and collaborated with improdia.co.il. H.S. reports honoraria for teaching, consultancy and advisory boards from BMS, Roche, Merck and Novartis. J.S.W. receives travel grants from and participated to scientific advisory boards of BMS, Merck, Astra-Zeneca, Genentech and EMD Serono. A.M. received consulting honoraria from Roche/Genentech, BMS, Merck (MSD), Astra-Zeneca and participated to scientific advisory boards of Roche/Genentech, Pfizer/Merck serono, Novartis, GSK, eTherna, Kyowa Kirin, Symphogen, Genmab, Amgen, Lytix, Nektar, Seatlle Genetics, Transgene and Flexus Bio. The remaining authors declare no competing financial interests.
